Top Qs
Timeline
Chat
Perspective
BK-5F-NM-AMT
Pharmaceutical compound From Wikipedia, the free encyclopedia
Remove ads
BK-5F-NM-AMT, or βk-5F-NM-αMT, also known as β-keto-5-fluoro-N-methyl-αMT or α,N-dimethyl-5-fluoro-β-ketotryptamine, is a monoamine releasing agent of the tryptamine, α-alkyltryptamine, and β-ketotryptamine families.[1]
It is known to induce the release of serotonin and dopamine, with respective EC50 values of 190 nM and 620 nM in rat brain synaptosomes, whereas norepinephrine release was not reported.[1] In contrast to many other tryptamines, the drug is inactive as an agonist of serotonin receptors including the 5-HT1, 5-HT2, and 5-HT3 receptors.[1] In addition, unlike other α-alkyltryptamines like α-methyltryptamine (αMT), it is inactive as a monoamine oxidase inhibitor (MAOI).[1]
BK-5F-NM-AMT was first described in the literature by 2023.[1] It was patented by Matthew Baggott and Tactogen as a potential novel entactogen.[1] BK-5F-NM-AMT is the 5-fluoro derivative of BK-NM-AMT.[1][2][3][4] Other analogues of the drug include BK-5Cl-NM-AMT and BK-5Br-NM-AMT.[1]
Remove ads
See also
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads